Background: The use of psychotropic medications is not uncommon among patients with newly diagnosed cancer. However, the impact of psychotropic polypharmacy on healthcare utilization during the initial phase of cancer care is largely unknown.
Methods: We used a claims database to identify adults with incident breast, prostate, lung, and colorectal cancers diagnosed during 2011-12. Psychotropic polypharmacy was defined as concurrent use of two or more psychotropic medication classes for at least 90 days. A multivariable logistic regression was performed to identify significant predictors of psychotropic polypharmacy. Multivariable Poisson and negative binomial regressions were used to assess the associations between psychotropic polypharmacy and healthcare utilization.
Results: Among 5604 patients included in the study, 52.6% had breast cancer, 30.6% had prostate cancer, 11.4% had colorectal cancer, and 5.5% had lung cancer. During the year following incident cancer diagnosis, psychotropic polypharmacy was reported in 7.4% of patients, with the highest prevalence among patients with lung cancer (14.4%). Compared with patients without psychotropic polypharmacy during the initial phase of care, patients with newly diagnosed cancer with psychotropic polypharmacy had a 30% higher rate of physician office visits, an 18% higher rate of hospitalization, and a 30% higher rate of outpatient visits. The rate of emergency room visits was similar between the two groups.
Conclusion: Psychotropic polypharmacy during the initial phase of cancer care was associated with significantly increased healthcare resource utilization, and the proportion of patients receiving psychotropic polypharmacy differed by type of cancer.
Impact: Findings emphasize the importance of evidence-based psychotropic prescribing and close surveillance of events causing increased healthcare utilization among patients with cancer receiving psychotropic polypharmacy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520416 | PMC |
| http://dx.doi.org/10.1007/s40801-019-0153-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clozapine treatment continues to be recognized as the gold standard for managing treatment-resistant schizophrenia. Combining clozapine with other antipsychotics (i.e.
View Article and Find Full Text PDFTherapeutic drug monitoring vs. pharmacogenetic testing in the context of elevated olanzapine concentrations and prior clozapine intolerability: a case study.
BMC Psychiatry
December 2024
University of California, Irvine, School of Medicine, 1001 Health Sciences Road, Irvine, CA, 92697, USA.
Article Synopsis
- Strong evidence supports therapeutic drug monitoring (TDM) for olanzapine and clozapine, but TDM for olanzapine is often underused despite its effectiveness.
- A case study of a 32-year-old male with schizoaffective disorder demonstrated that while olanzapine dosing revealed high levels indicating poor metabolism, pharmacogenetic tests did not provide useful information about his drug metabolism.
- The conclusion emphasizes the importance of TDM over pharmacogenomic testing for managing medications like olanzapine and clozapine, especially in patients suspected of having altered CYP1A2 metabolism.
Personality disorders and schizophrenia spectrum disorders in the Italian forensic psychiatric population: clinical features, pattern of violence and treatment.
Int Rev Psychiatry
November 2024
Interdisciplinary Department of Medicine, Section of Criminology and Forensic Psychiatry, University of Bari "Aldo Moro", Bari, Italy.
Article Synopsis
- Since 2015, Residencies for Execution of Security Measures (REMS) in Italy have treated dangerous offenders acquitted for mental disorders, primarily those with schizophrenia spectrum disorders (SSD) and personality disorders (PD).
- The study analyzed data from 528 REMS patients, revealing that the PD group had more females and substance abuse issues, while the SSD group often involved serious offenses like homicide.
- Findings suggest that patients with PD show more violent behavior in REMS, while SSD patients are treated with higher doses and combinations of antipsychotics, highlighting the need for tailored treatment approaches.
Investigating pain-related medication use and contribution to polypharmacy in adults with intellectual disabilities: a systematic review.
BMC Med
December 2024
General Practice & Primary Care, School of Health & Wellbeing, University of Glasgow, Glasgow, G12 8TB, UK.
Background: Adults with intellectual disability experience more pain than adults without and, despite a higher number of medications being prescribed, may be less likely to receive medication for pain. We conducted a systematic review of existing literature on medication for pain and painful conditions in adults with intellectual disability to explore if there is any association with polypharmacy, multimorbidity or demographic characteristics.
Methods: This systematic review followed PRISMA guidelines.
Drug prescriptions in elderly hospitalized patients with cognitive impairment in the Italian Dementia Friendly Hospital project.
Front Pharmacol
November 2024
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Objective: The aim of the study was to characterize drug prescription patterns in elderly patients hospitalized in acute wards as a function of cognitive status and staff training.
Methods: We recorded clinical parameters reflecting health status and drug prescriptions at admission, during hospital stay, and at discharge before and after a short staff training on the needs of aged cognitively impaired patients. Participants aged 65 and older had a Mini-Mental State Examination (MMSE) score ≥16.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!